General form of registration statement for all companies including face-amount certificate companies

SHAREHOLDERS' EQUITY (Tables)

v3.22.0.1
SHAREHOLDERS' EQUITY (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Schedule of stock options activity

Options Outstanding

    

    

Weighted

    

Weighted

    

Average

Average

Number of

Exercise

Remaining

Aggregate

Shares Subject

Price Per

Contractual

Intrinsic Value

to Options

Share

Life (in years)

(in thousands)

Balance at December 31, 2020

 

748,600

$

5.25

4.00

Options granted

 

348,000

5.33

Options exercised

 

(3,000)

6.40

Options canceled / expired

 

(79,500)

5.96

Balance at September 30, 2021

 

1,014,100

5.16

 

3.62

 

$

2,670

Vested and exercisable at September 30, 2021

 

636,008

4.93

 

3.39

 

$

1,894

Options Outstanding

    

    

Weighted

    

Weighted

    

Average

Average

Number of

Exercise

Remaining

Aggregate

Shares Subject

Price Per

Contractual

Intrinsic Value

to Options

Share

Life (in years)

(in thousands)

Balance at December 31, 2018

 

3,335,000

$

0.48

 

  

 

  

Options granted

 

1,501,000

$

1.56

Options exercised

 

(650,000)

$

0.15

Options canceled / expired

 

(1,000,000)

$

0.05

Balance at December 31, 2019

 

3,186,000

$

1.12

4.62

Options granted

 

865,000

$

0.95

Options exercised

 

(50,000)

$

0.50

Options canceled / expired

 

(258,000)

$

1.60

Balance at December 31, 2020

 

3,743,000

$

1.05

 

4.00

 

$

1,053

Vested and exercisable at December 31, 2020

 

2,352,601

$

0.95

 

3.98

 

$

995

Schedule of stock options outstanding and exercisable

Options Outstanding

Options Exercisable

    

Weighted

    

    

    

Average

Weighted

Weighted

Remaining

Average

Average

Number of

Contractual

Exercise Price

Number

Exercise Price

Outstanding

Life (in years)

Per Share

Exercisable

Per Share

200,000

 

3.90

$

0.25

 

200,000

$

0.25

12,000

 

1.07

$

14.00

 

12,000

$

14.00

15,000

 

6.30

$

9.00

 

15,000

$

9.00

85,000

 

2.00

$

9.00

 

73,667

$

9.00

146,800

 

2.30

$

7.80

 

127,227

$

7.80

81,300

 

3.01

$

6.40

 

48,780

$

6.40

40,000

3.91

$

4.50

18,667

$

4.50

93,000

 

4.20

$

4.85

 

31,000

$

4.85

311,000

4.34

$

5.30

103,667

$

5.30

30,000

4.54

$

5.60

6,000

$

5.60

1,014,100

 

3.62

$

5.16

 

636,008

$

4.93

Options Outstanding

Options Exercisable

    

Weighted

    

    

    

Average

Weighted

Weighted

Remaining

Average

Average

Number of

Contractual

Exercise Price

Number

Exercise Price

Outstanding

Life (in years)

Per Share

Exercisable

Per Share

1,000,000

 

4.65

$

0.05

 

1,000,000

$

0.05

60,000

 

1.82

$

2.80

 

60,000

$

2.80

75,000

 

7.05

$

1.80

 

75,000

$

1.80

425,000

 

2.75

$

1.80

 

311,667

$

1.80

884,000

 

3.04

$

1.56

 

530,401

$

1.56

434,000

 

3.76

$

1.28

 

202,533

$

1.28

300,000

4.66

$

0.90

60,000

$

0.90

565,000

 

4.95

$

0.97

 

113,000

$

0.97

3,743,000

 

4.00

$

1.05

 

2,352,601

$

0.95

Schedule of assumptions were used to determine fair value of the awards

    

Nine Months Ended September 30,

 

2021

    

2020

Expected life (in years)

 

5.0

 

5.0

Risk-free interest rate

 

0.4

%  

3.0

%

Dividend yield

 

%  

%

Expected volatility

 

91

%  

107

%

    

Years Ended December 31,

 

2020

    

2019

Expected life (in years)

 

5.0

 

5.0

Risk-free interest rate

 

0.4-2.5

%  

2.0

%

Dividend yield

 

%  

%

Expected volatility

 

91-107

%  

100

%

Schedule of changes in stock option liability  

Balance at December 31, 2018

    

$

246

Loss on revaluation

 

8

Reclassification option fair value at exercise to equity

 

(188)

Balance at December 31, 2019

$

66

Gain on revaluation

 

(50)

Balance at December 31, 2020

$

16

Schedule of warrants

    

Number of Warrants outstanding

Balance at December 31, 2020

 

3,665,006

Debenture, warrants issued (Note 4)

 

275,000

Balance at September 30, 2021

 

3,940,006

    

Number of Warrants outstanding

Balance at December 31, 2018

 

49,000

Warrants exercised

 

(44,600)

Warrants expired

(4,400)

Convertible debt, warrants issued (Note 8)

 

392,755

Balance at December 31, 2019

 

392,755

Convertible debt, warrants issued (Note 8)

 

1,511,609

Equity financing, warrants issued (discussed above)

 

16,420,664

Balance at December 31, 2020

 

18,325,028

Schedule of average exercise price of the outstanding warrants  

Balance at December 31, 2018

    

$

56

Loss on revaluation

 

14

Reclassification warrant fair value at exercise to equity

 

(70)

Balance at December 31, 2019

$

Schedule of warrants, valuation assumptions  

    

Year Ended

Year Ended

December 31, 2020

    

December 31, 2019

Risk free rate of return

0.39

%

1.64

%

Expected life

5.0

years  

4.0

years

Expected volatility

90

%

171

%

Expected dividend per share

nil

nil

Exercise price

$

0.78

$

1.40

Stock price

$

0.96

$

1.31

Consultant [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Schedule of assumptions were used to determine fair value of the awards  

    

Years Ended December 31,

2020

    

2019

Risk free rate of return

0.1

%

1.7

%

Expected life

1.8

years

2.8

years

Expected volatility

100

%

170

%

Expected dividend per share

nil

nil